Promising therapeutic targets in BTKi- and BCL2i-resistant patients with CLL. Mechanisms of inhibition in advanced clinical development are depicted with solid lines, while those with more preliminary data are represented in dotted lines. CDKi, cyclin-dependent kinase inhibitors; ERKi, extracellular signal–regulated kinase inhibitors; MCL1i, myeloid leukemia 1 inhibitors. The figure was created with BioRender.